{
    "clinical_study": {
        "@rank": "20130", 
        "arm_group": [
            {
                "arm_group_label": "CBT with booster sessions", 
                "arm_group_type": "Experimental", 
                "description": "Participants will receive 12 cognitive-behavioral therapy sessions weekly and 3 booster sessions monthly following our protocol."
            }, 
            {
                "arm_group_label": "CBT only", 
                "arm_group_type": "Active Comparator", 
                "description": "Participants will only receive 12 cognitive-behavioral therapy sessions weekly."
            }, 
            {
                "arm_group_label": "waiting", 
                "arm_group_type": "No Intervention", 
                "description": "Participations will not be treated with CBT and keep waiting for 12 weeks for comparison."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether cognitive behavioral therapy (CBT) is\n      effective in the treatment of attention deficit and emotional, executive function and social\n      function dysregulation due to attention deficit disorder (ADHD)."
        }, 
        "brief_title": "A Randomized Controlled Study of Cognitive Behavioral Therapy for Adults With Attention Deficit Disorder", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Attention Deficit Disorder", 
        "condition_browse": {
            "mesh_term": "Attention Deficit Disorder with Hyperactivity"
        }, 
        "detailed_description": {
            "textblock": "Participations will be randomly assigned to 3 groups which are CBT with booster sessions\n      group, CBT only group and waiting group.With the comparison of first tow groups we will\n      explore the effect of booster sessions, and the last two groups the effect of CBT programme."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Outpatients from Peking University Sixth Hospital\n\n          -  Diagnosis of adult ADHD based on Diagnostic and statistical manual of mental\n             disorders, Fourth Edition (DSM-IV)\n\n          -  Stable on medications for adult ADHD for at least 2 months\n\n        Exclusion Criteria:\n\n          -  Severe major depression, clinically significant panic disorder, bipolar disorder,\n             organic mental disorders, psychotic disorders, or pervasive developmental disorders\n\n          -  Intelligence Quotient (IQ) less than 90\n\n          -  Suicide risk\n\n          -  Unstable physical condition\n\n          -  Prior participation in cognitive behavioral therapy for ADHD or other psychological\n             therapy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "73", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02062411", 
            "org_study_id": "2013\uff0d9\uff0d23\uff0d3"
        }, 
        "intervention": [
            {
                "arm_group_label": "CBT only", 
                "description": "Participants will learn 12 sessions including educational information about ADHD and skills in organization and plan, reducing distractibility, and adaptive thinking.", 
                "intervention_name": "CBT only", 
                "intervention_type": "Behavioral", 
                "other_name": "Mastering Your Adult ADHD manual (Safren, et al., 2005)"
            }, 
            {
                "arm_group_label": "CBT with booster sessions", 
                "description": "Participants are provided with the same CBT programme and additional 3 booster sessions which summarize and extend the 3 main topics of the CBT programme in order to improve the skills practice ability.", 
                "intervention_name": "CBT with booster sessions", 
                "intervention_type": "Behavioral"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "attention deficit disorder (ADHD)", 
            "cognitive behavioral therapy (CBT)", 
            "adult"
        ], 
        "lastchanged_date": "February 12, 2014", 
        "location": {
            "contact": {
                "email": "qianqiujin@bjmu.edu.cn", 
                "last_name": "Qiujin Qian, PhD", 
                "phone": "0086-01-82802907"
            }, 
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "state": "Beijing", 
                    "zip": "100191"
                }, 
                "name": "Peking University Sixth Hospital"
            }, 
            "investigator": [
                {
                    "last_name": "Qiujin Qian, PhD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Fang Huang, Master", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized Controlled Study of Cognitive Behavioral Therapy for Adults With Attention Deficit Disorder", 
        "overall_contact": {
            "email": "qianqiujin@bjmu.edu.cn", 
            "last_name": "Qiujin Qian, PhD", 
            "phone": "0086-10-82802907"
        }, 
        "overall_official": {
            "affiliation": "Peking University Sixth Hospital", 
            "last_name": "Qiujin Qian, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "ADHD symptom severity as measured by the ADHD rating scale (DuPaul, et al., 1998) a scale that ranges from 0-54 with 0 indicating lower severity.", 
            "measure": "Change in ADHD Rating Scale", 
            "safety_issue": "No", 
            "time_frame": "Baseline, at the end of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 in treatment, 12 weeks (post), 24 weeks (FU6), 36 weeks (FU9), and 48 weeks (FU12)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02062411"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking University Sixth Hospital", 
            "investigator_full_name": "Qiujin Qian", 
            "investigator_title": "PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The CAARS-S:SV is a self-reported scale measures the ADHD symptom severity including 30 items rating from 0 to 3.", 
                "measure": "Change in Conners Adult ADHD Rating Scale Self-report Screening Version (CAARS-S:SV)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, at the end of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 in treatment, 12 weeks (post), 24 weeks (FU6), 36 weeks (FU9), and 48 weeks (FU12)"
            }, 
            {
                "description": "The Self-Rating Anxiety Scale (SAS) with 20 items measures the level of anxiety.", 
                "measure": "Change in Self-Rating Anxiety Scale (SAS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, at the end of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 in treatment, 12 weeks (post), 24 weeks (FU6), 36 weeks (FU9), and 48 weeks (FU12)"
            }, 
            {
                "description": "The Self-rating depression scale (SDS) is used to measure the level of depression.", 
                "measure": "Change in Self-rating depression scale (SDS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, at the end of week 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 in treatment, 12 weeks (post), 24 weeks (FU6), 36 weeks (FU9), and 48 weeks (FU12)"
            }, 
            {
                "description": "The BRIEF-A measures the impairment level of executive function in ADHD adults.", 
                "measure": "Change in Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 weeks (post), 24 weeks (FU6), and 48 weeks (FU12)"
            }, 
            {
                "description": "The CANTAB is a computerized neuropsychological test measuring the cognitive and executive function.", 
                "measure": "Change in Cambridge Neuropsychological Test Automatic Battery (CANTAB)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 weeks (post), 24 weeks (FU6), and 48 weeks (FU12)"
            }, 
            {
                "description": "The Barratt impulsiveness scale including 30 items is used to measure impulsiveness.", 
                "measure": "Change in Barratt impulsiveness scale (BIS)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 weeks (post), 24 weeks (FU6), and 48 weeks (FU12)"
            }, 
            {
                "description": "The self-esteem scale measures the level of self-esteem.", 
                "measure": "Change in self-esteem scale (SES)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 weeks (post), 24 weeks (FU6), and 48 weeks (FU12)"
            }, 
            {
                "description": "The WHOQOL-BREF is the short version of World Health Organization Quality of Life scale and includes 26 items measuring the level of life quality.", 
                "measure": "Change in World Health Organization Quality of Life-Brief Version (WHOQOL-BREF)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 weeks (post), 24 weeks (FU6), and 48 weeks (FU12)"
            }, 
            {
                "description": "The level of BOLD activity during working memory task after CBT is compared with baseline level to explore the potential effects of CBT on brain.", 
                "measure": "Change in Brain Oxygenation Level Dependent (BOLD) Signal", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 weeks (post)"
            }
        ], 
        "source": "Peking University Sixth Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking University Sixth Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}